Professur für Innere Medizin (Nephrologie)

New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension (2019) Papademetriou V, Stavropoulos K, Imprialos K, Doumas M, Schmieder R, Pathak A, Tsioufis C Journal article, Review article Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry (2019) Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, et al. Journal article Reduction in blood pressure following renal denervation for patients with differing baseline cardiovascular risk (2019) Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, Williams B, et al. Conference contribution Combined therapy of empagliflozin and linagliptin is superior to metformin and insulin glargine in improving blood pressure and vascular function in type 2 diabetes (2019) Jung S, Bosch A, Kannenkeril D, Karg M, Striepe K, Bramlage P, Ott C, Schmieder R Conference contribution Tissue sodium concentration emerged as a determinant of hypertrophic vascular remodeling in type 2 diabetes (2019) Schmieder R, Jung S, Kannenkeril D, Harazny JM, Striepe K, Ott C, Linz P, et al. Conference contribution Comeback of Renal Denervation As Treatment Option in Patients with Hypertension (2019) Jung S, Schmieder R Journal article Implementation of Bayesian Study Design in the SPYRAL HTN-OFF MED Pivotal Trial (2019) Boehm M, Townsend R, Weber M, Kandzari D, Mahfoud F, Kario K, Schmieder R, et al. Conference contribution Tissue sodium concentration correlates with hypertrophic vascular remodelling in type 2 diabetes (2019) Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Linz P, Nagel AM, et al. Conference contribution Pleiotropic effects under combined therapy with empagliflozin and linagliptin compared to metformin and insulin glargine in patients with type 2 diabetes (2019) Jung S, Ott C, Kannenkeril D, Bosch A, Karg M, Striepe K, Bramlage P, Schmieder R Conference contribution Disparate effects of the combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on renal haemodynamics in type 2 diabetes (2019) Ott C, Jung S, Kannenkeril D, Striepe K, Bosch A, Korn M, Bramlage P, Schmieder R Conference contribution